

CMP: ₹ 489

Target: ₹ 490 (0%)

Target Period: 12 months

February 8, 2022

Weak performance, CDMO, generics drag...

About the stock: Jubilant Pharmova is engaged in specialty pharmaceuticals, CDMO, generics, drug discovery and proprietary novel drug businesses.

- In specialty pharmaceuticals, it is the third largest radiopharmaceutical manufacturer with second largest commercial radio pharmacy network in US. It is the second biggest player in the allergenic extract market in the US
- In CDMO (CMO and APIs) Jubilant is an integrated contract manufacturer of sterile injectables, ophthalmics, otics and ointments (sterile and non-sterile), creams and liquids
- Revenue break up (FY21)- Formulations - 24%, Radiopharma and allergy therapy -38% and CDMO & API - 33%

Q3FY22 Results: Generics and CDMO business were affected due to multiple headwinds leading to reduction in operating leverage.

- Revenues were down 26% YoY to ₹ 1310.5 crore
- EBITDA was at ₹ 194.2 crore, down 60.6% YoY with margins at 14.8%
- Adjusted PAT was at ₹ 51 crore (down 77.8% YoY)

What should investors do? Jubilant's share price has de-grown by ~0.7x in the past five years (from ~₹ 704 in February 2017 to ~₹ 489 in February 2022) even after considering demerger of life science ingredients business into Jubilant Ingrevia.

- Maintain HOLD due to continued muted operational performance amid 1) slower-than-expected ramp-up in Radiopharma, 2) regulatory overhang in Generics and 3) waning Covid related contracts in CDMO.

Target Price and Valuation: Valued at ₹ 495 i.e. 12x P/E on FY24E EPS of ₹ 40.8

Key triggers for future price performance:

- Expansion of capacity for sterile fill & finish at Spokane by 50% and new ophthalmic line at Montreal
- Increase in CDMO order-book visibility amid shrinking Covid opportunities
- Embarking on executing turnaround plan in radio pharmacies with a target to achieve mid to high single digit EBITDA
- Resolving regulatory concerns over Roorkee and Nanjungud facility

Alternate Stock Idea: Apart from Jubilant, in CRAMs space we like Divi's.

- Divi's stays a quintessential play on Indian API/CRAMs segment with its product offering, execution prowess
- BUY with a target price of ₹ 5600

HOLD




Particulars

Particular	Amount
Market Capitalisation	₹ 7787 crore
Debt (FY21)	₹ 2830 crore
Cash (FY21)	₹ 742 crore
EV	₹ 9874 crore
52 week H/L (₹)	₹ 982/₹ 475
Equity capital	₹ 15.9 crore
Face value	₹ 1

Shareholding pattern

(in %)	Dec-20	Mar-21	Jun-21	Sep-21	Dec-21
Promoter	50.7	50.7	50.7	50.7	50.7
Others	49.3	49.3	49.3	49.3	49.3

Price Chart



Recent Event & Key risks

- Import alert for Roorkee facility
- Key Risk:** (i) Better traction in Radiopharma segment (ii) Regulatory concern

Research Analyst

Siddhant Khandekar
siddhant.khandekar@icicisecurities.com

Raunak Thakur
raunak.thakur@icicisecurities.com

Kush Mehta
kush.mehta@icicisecurities.com

Key Financial Summary

Key Financials (₹ crore)	FY20	FY21	5 year CAGR (FY16-21)	FY22E	FY23E	FY24E	3 year CAGR (FY21-24E)
Revenues	5975.8	6098.5	0.7	5968.2	6066.5	6784.6	3.6
EBITDA	1548.0	1396.5	2.3	1179.0	1267.7	1484.2	2.1
EBITDA Margins (%)	25.9	22.9		19.8	20.9	21.9	
Adjusted Net Profit	710.7	595.3	8.7	456.7	518.1	649.5	2.9
Reported EPS (₹)	42.6	36.0		28.7	32.5	40.8	
Adjusted EPS (₹)	44.6	37.4		28.7	32.5	40.8	
PE (x)	11.5	13.6		17.1	15.0	12.0	
EV/EBITDA (x)	7.2	7.1		8.4	7.5	6.1	
RoE (%)	12.7	12.6		8.9	9.2	10.4	
RoCE (%)	11.7	13.7		10.1	10.4	12.2	

Source: Company, ICICI Direct Research

Key takeaways of recent quarter & conference call highlights

Q3FY22 Results: Weak results amid multiple near term headwinds

- Revenues were at ₹ 1310.5 crore, down 26% YoY amid multiple headwinds in pharmaceutical segment. Generics declined 60.7% YoY to ₹ 181 crore and CDMO segment declined 42.6% YoY to ₹ 373 crore. Specialty pharma (which comprises Radiopharma) grew 8.8% YoY to ₹ 633 crore while contract research & development grew 51.9% YoY to ₹ 120 crore on the back of robust demand from customers. EBITDA margins declined 1300 bps YoY to 14.8%. EBITDA de-grew 60.6% YoY to ₹ 194.2 crore while adjusted PAT declined 77.8% to ₹ 51 crore
- Jubilant Pharmova Generics was affected by lower volumes due to Roorkee import alert, Sartan impurities issue and pricing pressure in US while loss of Covid related opportunities led to lower revenue and profitability in the CDMO business. API business was affected by unplanned shutdown this quarter and is likely to normalise in Q4FY22. Multiple issues converged in Q3 leading to dismal numbers and although Sartans issue has been resolved and exempted products sales have started in the US. We expect near to medium term overhang to remain amid regulatory concerns for Generics and resetting of base post loss of Covid opportunities in CDMO

Q3FY22 earnings conference call highlights

- Radiopharma was impacted due to rescheduling of some customer's orders amid surge in Covid cases in US. Allergy Immunotherapy continues to operate at volumes higher than pre-Covid levels
- Spike in Covid cases impacted Ruby-Fill installations during the quarter and pushed new installs to Q4FY22
- CMO business revenue was affected as revenue related to Covid related one-off deals tapered off and also on account of customer scheduling. The management expects the CMO segment to witness near term correction as Covid related product demand has subsided
- API business was affected due to lower volumes resulting from an unplanned plant shutdown during the quarter.
- Generics was impacted due to, 1) Impurity issue in certain Sartan products, 2) Lower volumes due to import alert at Roorkee plant, 3) Pricing pressure in the US and 4) Lower Remdesivir sales
- The management expects to complete remediation for Roorkee, in H1CY22
- The management expects generics business performance to improve, going forward, as the Sartans impurity issue has been resolved and exempted products sales in the US has restarted. However, pricing pressure in the US market is an overhang
- Contract research and development services witnessed higher demand from biotech companies for integrated services. DMPK expansion at Greater Noida is under way
- In the Proprietary Novel Drugs business, the company is on track to take lead drug candidate, – LSD1/HDAC6 inhibitor to Phase I clinical trials in Q4FY22 and has received FDA clearance of IND filing for same

Exhibit 1: Variance Analysis

	Q3FY22	Q3FY21	Q2FY22	YoY (%)	QoQ (%)	Comments
Revenue	1,310.5	1,771.3	1,657.5	-26.0	-20.9	YoY decline due to headwinds in pharmaceuticals segment
Raw Material Expenses	273.4	458.4	439.2	-40.4	-37.8	
Gross margins (%)	79.1	74.1	73.5	502 bps	564 bps	YoY increase due to increase in share of specialty pharma in sales-mix
Employee Expenses	524.5	482.1	509.3	8.8	3.0	
Other Expenditure	318.3	310.7	369.4	2.5	-13.8	
Total Expenditure	1,116.3	1,278.6	1,318.0	-12.7	-15.3	
EBITDA	194.2	492.8	339.5	-60.6	-42.8	
EBITDA (%)	14.8	27.8	20.5	-1300 bps	-566 bps	YoY decline mainly due to reduction in operating leverage
Interest	36.6	46.4	34.7	-21.0	5.4	
Depreciation	93.3	95.9	99.8	-2.7	-6.5	
Other income	5.9	3.6	4.5	64.6	32.8	
Exceptional Items	0.0	10.9	0.0	0.0	0.0	
PBT after Exceptional Items	70.2	343.2	209.4	-79.5	-66.5	
Tax	19.4	121.2	65.4	-84.0	-70.3	
Tax Rate (%)	27.7	35.3	31.2			
PAT before MI	50.8	222.0	144.0	-77.1	-64.8	
MI	-0.2	-0.1	-0.2	NA	NA	
Adj. Net Profit	51.0	229.9	142.8	-77.8	-64.3	YoY decline amid multiple challenges converging this quarter
Key Metrics						
Generics	181.0	460.0	330.0	-60.7	-45.2	Headwinds for generics due to pricing pressure in the US, Roorkee import alert and Sartan impurity issue Radiopharma gradual recovery was affected by increase in Covid-19 in
Specialty Pharma	633.0	582.0	651.0	8.8	-2.8	US. Allergy immunotherapy volumes have exceeded pre-Covid levels
CDMO	373.0	650.0	562.0	-42.6	-33.6	YoY decline amid loss of revenue related to Covid opportunity and also because of customer scheduling
Drug Discovery Solutions	120.0	79.0	108.0	51.9	11.1	Growth due to higher demand from biotech companies also supported by volume increase from recently commissioned facility at Greater Noida

Source: Company, ICICI Direct Research

Exhibit 2: Change in estimates

(₹ Crore)	FY22E			FY23E			FY24E		
	Old	New	Change	Old	New	Change	Introduced		
Revenue	7,135.8	5,968.2	-16.4	8,433.1	6,066.5	-28.1	6,784.6	Changed mainly due to headwinds in generics, less than expected traction in Radiopharma and CMO business	
EBITDA	1,548.1	1,179.0	-23.8	1,954.7	1,267.7	-35.1	1,484.2		
EBITDA Margi	21.7	19.8	-194 bps	23.2	20.9	-228 bps	21.9	Changed mainly due to US price erosion and lower-than-expected operating leverage	
PAT	700.9	456.7	-34.8	997.5	518.1	-48.1	649.5		
EPS (₹)	44.0	28.7	-34.8	62.6	32.5	-48.1	40.8		

Source: ICICI Direct Research

Exhibit 3: Assumptions

	Revenues	Growth	Adj. EPS	Growth	P/E	EV/EBITDA	RoNW	RoCE
	(₹ crore)	(%)	(₹)	(%)	(x)	(X)	(%)	(%)
FY21	6099	2.1	37.4	-15.3	13.6	7.1	12.6	13.7
FY22E	5968	-2.1	28.7	-20.5	17.1	8.4	8.9	10.1
FY23E	6066	1.6	32.5	13.5	15.0	7.5	9.2	10.4
FY24E	6785	11.8	40.8	25.4	12.0	6.1	10.4	12.2

Source: ICICI Direct Research

Exhibit 4: ICICI Direct Coverage Universe (Healthcare)

Company	I-Direct Code	CMP (₹)	TP (₹)	Rating	M Cap (₹ cr)	EPS (₹)				PE(x)				RoCE (%)				RoE (%)			
						FY20	FY21	FY22E	FY23E	FY20	FY21	FY22E	FY23E	FY20	FY21	FY22E	FY23E	FY20	FY21	FY22E	FY23E
Hospitals																					
Apollo Hospitals	APOHOS	4475	5,930	Buy	64346	22.6	7.9	72.9	99.4	198.2	569.3	61.4	45.0	10.2	6.3	18.1	21.7	9.7	2.5	18.6	20.9
Narayana Hrudalaya	NARHRU	662	795	Buy	13529	6.4	-0.7	17.4	19.9	104.2	NA	38.0	33.2	11.0	1.2	21.0	22.3	11.4	-1.3	24.4	22.1
Shalby	SHALIM	142	170	Buy	1532	2.6	3.9	5.9	5.8	55.5	36.1	24.0	24.5	7.2	6.5	8.9	9.6	3.5	5.1	7.2	6.7
Aster DM	ASTDM	184	250	Buy	9201	5.7	3.0	10.6	17.2	32.3	62.3	17.4	10.7	7.2	5.4	8.7	12.1	8.7	4.4	13.5	18.0
Healthcare Global	HEAGLO	253	240	Hold	3173	-12.0	-21.7	15.6	8.4	NA	NA	16.3	30.0	1.0	-0.9	7.6	10.4	NA	NA	NA	7.2
MNC Pharma																					
Abbott India	ABBIND	15790	20,360	Buy	33553	279.0	325.0	362.3	471.9	56.6	48.6	43.6	33.5	30.7	33.8	35.3	37.2	24.4	26.5	27.6	28.9
P&G Health	MERLIM	5048	6,555	Buy	8380	102.0	106.5	135.7	145.7	49.5	47.4	37.2	34.7	24.0	32.2	41.0	37.7	18.7	25.1	31.6	28.8
Sanofi India	SANOFI	7390	9,800	Buy	17020	179.8	207.4	431.8	280.0	41.1	35.6	17.1	26.4	26.0	32.3	34.2	41.9	19.4	24.5	22.2	33.5
Pfizer	PFIZER	4407	5,350	Buy	20161	111.3	108.8	135.2	133.0	39.6	40.5	32.6	33.1	18.5	27.6	27.4	23.6	15.0	20.8	21.7	18.6
Pharma																					
Ajanta Pharma	AJAPHA	2113	2,500	Buy	18285	53.4	74.0	79.3	89.3	39.6	28.6	26.6	23.7	24.7	29.0	25.2	23.8	18.1	21.8	19.9	19.2
Alembic Pharma	ALEMPHA	733	790	Hold	14403	44.4	59.9	33.3	39.6	16.5	12.2	22.0	18.5	21.0	24.2	11.9	13.9	27.1	23.0	11.7	12.6
Aurobindo Pharma	AURPHA	651	795	Hold	38145	48.8	55.0	50.3	61.2	13.4	11.8	12.9	10.6	17.2	16.9	13.8	15.2	17.0	14.7	11.9	12.8
Biocon	BIOCON	399	380	Hold	47916	5.8	6.1	5.4	9.3	68.6	65.6	74.2	43.0	10.2	7.6	7.8	10.0	10.4	9.6	7.9	12.2
Cadila Healthcare	CADHEA	397	477	Hold	40678	14.0	21.5	20.9	21.8	28.4	18.5	19.0	18.2	10.7	12.6	13.4	13.4	13.8	16.9	14.7	13.7
Cipla	CIPLA	933	1,085	Buy	75267	19.2	29.9	34.6	41.8	48.6	31.2	26.9	22.3	12.0	16.3	17.8	18.4	9.8	13.1	13.7	14.6
Dr Reddy's Labs	DRREDD	4309	5,170	Hold	71688	121.8	117.3	181.2	204.2	35.4	36.7	23.8	21.1	9.6	13.1	16.3	17.3	13.0	11.1	14.9	14.7
Glenmark Pharma	GLEPHA	490	580	Hold	13821	26.4	32.9	37.7	43.7	18.6	14.9	13.0	11.2	12.7	13.9	15.3	15.9	12.2	13.1	12.5	12.7
Ipsca Laboratories	IPCLAB	1020	2,490	Buy	12943	47.6	89.9	78.0	95.8	21.5	11.4	13.1	10.6	17.6	27.1	20.5	20.9	16.6	24.2	17.5	17.7
Jubilant Pharmova	JUBLIF	489	490	Hold	7793	44.6	37.4	28.7	32.5	11.0	13.1	17.1	15.0	11.7	13.7	10.1	10.4	12.7	12.6	8.9	9.2
Lupin	LUPIN	805	960	Hold	36526	-12.7	26.9	16.2	30.2	NA	30.0	49.7	26.7	9.7	9.1	6.1	10.5	-4.6	8.8	5.8	9.6
Natco Pharma	NATPHA	904	925	Hold	16484	25.3	24.2	17.1	20.1	35.8	37.4	52.9	44.9	14.0	13.1	8.4	9.9	12.2	10.7	7.2	8.0
Sun Pharma	SUNPHA	886	965	Buy	212605	16.8	30.0	30.6	32.2	52.8	29.5	28.9	27.5	10.0	14.2	16.7	16.3	8.9	15.5	14.2	13.2
Torrent Pharma	TORPHA	2607	3,110	Hold	44118	60.6	74.0	78.3	103.7	43.0	35.2	33.3	25.1	15.4	17.7	21.0	22.6	21.2	21.4	19.4	21.5
Indoco Remedies	INDREM	378	575	Buy	3490	2.6	10.1	17.3	23.9	144.4	37.4	21.8	15.8	4.6	11.7	19.8	21.5	3.5	12.1	17.6	20.2
Caplin Point	CAPPOI	801	1,010	Buy	6055	17.2	81.7	76.7	55.5	46.6	9.8	10.4	14.4	25.4	25.6	24.1	23.5	22.7	20.4	20.5	18.8
Advanced Enzymes	ADVENZ	321	420	Buy	3591	11.6	13.1	13.0	16.1	27.8	24.6	24.6	20.0	19.6	19.4	16.8	18.3	15.4	15.1	13.2	14.1
Hester Biosciences	HESPHA	2451	2,780	Hold	2085	34.3	44.4	47.2	52.0	71.5	55.2	52.0	47.2	14.0	16.2	12.8	14.3	14.5	16.5	15.5	15.1
API/CRAMS																					
Divi's Lab	DIVLAB	4202	5,815	Buy	111537	51.9	74.7	90.6	107.5	81.0	56.2	46.4	39.1	23.9	27.6	27.7	27.7	18.8	21.3	21.8	21.8
Hikal	HIKCHE	423	640	Buy	5218	8.1	10.8	17.2	21.4	52.3	39.2	24.6	19.8	12.8	15.1	17.7	18.5	12.2	14.3	18.7	19.1
Syngene Int.	SYNINT	574	710	Buy	22978	10.3	10.1	9.8	13.9	55.8	56.7	58.7	41.2	14.5	11.5	12.6	15.5	16.8	13.5	13.2	14.9
Granules India	GRANUL	311	350	Hold	7704	12.4	22.2	15.0	23.3	25.0	14.0	20.7	13.3	15.2	24.0	16.1	21.7	16.7	25.3	14.8	18.9
Laurus Labs	LAULAB	529	670	Buy	28367	4.8	18.3	17.6	23.9	111.1	28.8	30.0	22.1	13.0	31.7	25.1	28.0	14.4	37.9	27.4	27.9
Suven Pharmaceuticals	SUVPH	561	600	Buy	14289	12.5	14.2	15.0	18.7	45.1	39.4	37.3	29.9	35.6	31.2	25.7	24.7	37.5	30.7	24.9	23.9

Source: ICICI Direct Research

Financial Summary

Exhibit 5: Profit and loss statement				
	₹ crore			
(Year-end March)	FY21	FY22E	FY23E	FY24E
Revenues	6,098.5	5,968.2	6,066.5	6,784.6
Growth (%)	2.1	-2.1	1.6	11.8
Raw Material Expenses	1,536.0	1,421.4	1,523.8	1,696.2
Employee Expenses	1,922.9	1,952.6	1,850.3	2,061.2
Selling & Admin expenses	1,137.4	1,386.4	1,424.7	1,543.1
Power cost	105.8	28.7	0.0	0.0
Total Operating Expenditure	4,702.1	4,789.2	4,798.7	5,300.5
EBITDA	1,396.5	1,179.0	1,267.7	1,484.2
Growth (%)	-9.8	-15.6	7.5	17.1
Depreciation	349.0	376.0	435.4	494.8
Interest	184.1	142.6	120.6	94.7
Other Income	17.6	20.4	18.0	20.2
PBT before EO	881.1	680.8	729.8	914.8
Less: Exceptional Items	21.2	0.0	0.0	0.0
Total Tax	297.2	212.8	211.6	265.3
Minority Interest	-0.3	0.0	0.0	0.0
PAT	574.1	456.7	518.1	649.5
Growth (%)	-15.3	-20.5	13.5	25.4
EPS	36.0	28.7	32.5	40.8
Adjusted PAT	595.3	456.7	518.1	649.5
EPS (Adjusted)	37.4	28.7	32.5	40.8

Source: Company, ICICI Direct Research

Exhibit 6: Cash flow statement				
	₹ crore			
(Year-end March)	FY21	FY22E	FY23E	FY24E
Profit/(Loss) after taxation	817.9	456.7	518.1	649.5
Add: Depreciation	451.7	376.0	435.4	494.8
Add: Interest paid	247.3	142.6	142.6	142.6
(Inc)/dec in Current Assets	21.6	-128.6	-48.7	-259.9
Inc/(dec) in CL and Provisions	228.3	21.2	47.8	106.6
Other Operating Activities	0.0	0.0	0.0	0.0
CF from operating activities	1,766.7	867.8	1,095.2	1,133.6
(Purchase)/Sale of FA	-514.3	-600.0	-500.0	-500.0
Deferred Tax Liability	0.0	7.4	7.6	7.9
Minority Interest	0.0	0.0	0.0	0.0
Investments	-202.4	0.0	0.0	0.0
Other Investing Activities	-86.7	-13.8	-15.3	-16.9
CF from investing activities	-803.4	-606.3	-507.6	-509.0
Inc/(Dec) in Equity Capital	-10.1	0.0	0.0	0.0
Inc/(Dec) in Loan Funds	-1,405.6	0.0	-500.0	-500.0
Dividend & Dividend tax	-1.5	-47.8	-47.8	-47.8
Less: Interest Paid	-247.3	-142.6	-142.6	-142.6
Others	-44.9	0.0	0.0	0.0
CF from financing activities	-1,709.4	-190.4	-690.4	-690.4
Net Cash flow	-746.1	71.1	-102.8	-65.9
Opening Cash	1,399.9	671.3	742.4	639.6
Closing Cash	653.8	742.4	639.6	573.8
Free Cash Flow	1,252.4	267.8	595.2	633.6

Source: Company, ICICI Direct Research

Exhibit 7: Balance Sheet				
	₹ crore			
(Year-end March)	FY21	FY22E	FY23E	FY24E
Equity Capital	15.9	15.9	15.9	15.9
Reserve and Surplus	4,725.6	5,134.5	5,604.8	6,206.5
Total Shareholders funds	4,741.5	5,150.4	5,620.7	6,222.4
Total Debt	2,829.6	2,829.6	2,329.6	1,829.6
Deferred Tax Liability	247.3	254.7	262.4	270.2
Minority Interest	0.0	0.0	0.0	0.0
Other Non CL & LT Provisions	121.1	124.7	128.4	132.3
Total Liabilities	7,939.4	8,359.4	8,341.1	8,454.5
Gross Block - Fixed Assets	4,027.2	4,427.2	5,127.2	5,827.2
Accumulated Depreciation	1,548.5	1,924.4	2,359.8	2,854.7
Net Block	2,478.8	2,502.8	2,767.4	2,972.6
Capital WIP	897.0	1,097.0	897.0	697.0
Total Fixed Assets	3,375.8	3,599.8	3,664.4	3,669.6
Investments	241.0	241.0	241.0	241.0
Goodwill on Consolidation	2,130.0	2,130.0	2,130.0	2,130.0
Inventory	1,129.4	1,179.4	1,201.3	1,343.5
Debtors	819.9	888.6	905.1	1,012.2
Cash	671.3	742.4	639.6	573.8
Other current Assets	331.9	341.9	352.1	362.7
Total Current Assets	2,952.5	3,152.2	3,098.1	3,292.2
Creditors	520.5	508.9	518.4	579.7
Provisions	89.8	111.5	138.5	172.0
Other Current Liabilities	368.4	379.5	390.8	402.6
Total Current Liabilities	978.7	999.9	1,047.7	1,154.3
Net Current Assets	1,973.8	2,152.3	2,050.4	2,137.9
Deferred Tax Assets	154.7	170.2	187.2	205.9
LT L & A, Other Non CA	64.2	66.1	68.1	70.2
Application of Funds	7,939.4	8,359.4	8,341.1	8,454.5

Source: Company, ICICI Direct Research

Exhibit 8: Key ratios				
(Year-end March)	FY21	FY22E	FY23E	FY24E
Per share data (₹)				
Reported EPS	36.0	28.7	32.5	40.8
Adjusted EPS	37.4	28.7	32.5	40.8
BV per share	297.7	323.4	352.9	390.7
Dividend per share	5.0	3.0	3.0	3.0
Cash Per Share	42.1	46.6	40.2	36.0
Operating Ratios (%)				
Gross Profit Margins	74.8	76.2	74.9	75.0
EBITDA Margins	22.9	19.8	20.9	21.9
PAT Margins	9.8	7.7	8.5	9.6
Inventory days	67.6	72.1	72.3	72.3
Debtor days	49.1	54.3	54.5	54.5
Creditor days	31.2	31.1	31.2	31.2
Asset Turnover	2.3	1.3	1.2	1.1
EBITDA conversion Rate	126.5	73.6	86.4	76.4
Return Ratios (%)				
RoE	12.6	8.9	9.2	10.4
RoCE	13.7	10.1	10.4	12.2
RoIC	14.7	10.8	11.1	12.9
Valuation Ratios (x)				
P/E	13.6	17.1	15.0	12.0
EV / EBITDA	7.1	8.4	7.5	6.1
EV / Net Sales	1.6	1.7	1.6	1.3
Market Cap / Sales	1.3	1.3	1.3	1.1
Price to Book Value	1.6	1.5	1.4	1.3
Solvency Ratios				
Debt / Equity	0.6	0.5	0.4	0.3
Debt / EBITDA	2.0	2.4	1.8	1.2
Current Ratio	2.3	2.4	2.3	2.4

Source: Company, ICICI Direct Research

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

**ICICI Direct Research Desk,
ICICI Securities Limited,
1st Floor, Akruiti Trade Centre,
Road No 7, MIDC,
Andheri (East)
Mumbai – 400 093
research@icicidirect.com**

ANALYST CERTIFICATION

I/We, Siddhant Khandekar, Inter CA, Raunak Thakur, PGDM, Kush Mehta, CA, Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc. as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.